<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03780933</url>
  </required_header>
  <id_info>
    <org_study_id>247</org_study_id>
    <nct_id>NCT03780933</nct_id>
  </id_info>
  <brief_title>the Effect of High Dose Ascorbic Acid on Critically Ill Patients With ARDS</brief_title>
  <official_title>The Impact of High Dose Vitamin C &quot;Ascorbic Acid&quot; on the Clinical Outcomes of Critically Ill Patients With Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Misr International University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Misr International University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To access role of vitamin C supplementation in ARDS patients on the following:&#xD;
&#xD;
           Oxidants/ antioxidants imbalance Length of hospital stay Mortality rate Weaning from&#xD;
           mechanical ventilator Incidence of adverse drug reaction&#xD;
&#xD;
        2. To access tolerability of vitamin C supplementation in patients with ARDS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute Respiratory distress syndrome (ARDS) is a form of severe hypoxemic respiratory failure&#xD;
      due to severe impairment of gas exchange and lung mechanics that is characterized by&#xD;
      inflammatory injury to the alveolar capillary barrier, with extravasation of protein-rich&#xD;
      edema fluid into the air space. Current ARDS antioxidant treatment strategy, is based upon&#xD;
      supportive therapies including low tidal volume ventilation, fluid management, nutritional&#xD;
      support and glucocorticoids.&#xD;
&#xD;
      Ascorbic acid or Vitamin C is an important dietary water-soluble antioxidant, it&#xD;
      significantly decreases the adverse effects of ROS such as reactive oxygen and nitrogen&#xD;
      species that can cause oxidative damage to macromolecules. Recent studies show that high dose&#xD;
      of Vitamin C have protective effects against overwhelming oxidative stress due to critical&#xD;
      illness. Vitamin C improves immune function and improves tissue perfusion and reduce tissue&#xD;
      hypoxia and subsequent organ dysfunction. Also, Ascorbate, the redox form of vitamin C is&#xD;
      physiological antioxidant and has bacteriostatic activity Hence the study aims to evaluate&#xD;
      the impact of IV Vitamin C in ARDS, as a novel pharmaceutical approach in an attempt to&#xD;
      improve the clinical outcome of ARDS patients, decrease other medications toxicities and&#xD;
      improve patients' quality of life.&#xD;
&#xD;
      The objective of the current study was to evaluate the efficacy, safety and tolerability of&#xD;
      IV Vitamin C administration in addition to conventional therapy in patients with ARDS by&#xD;
      assessing the following:&#xD;
&#xD;
        1. Oxidants/ antioxidants imbalance&#xD;
&#xD;
        2. Length of hospital stay&#xD;
&#xD;
        3. Mortality rate&#xD;
&#xD;
        4. Weaning from mechanical ventilator&#xD;
&#xD;
        5. Incidence of adverse drug reaction&#xD;
&#xD;
        6. Serum IL8 levels&#xD;
&#xD;
      8. Serum Vitamin C levels&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Actual">June 20, 2019</completion_date>
  <primary_completion_date type="Actual">June 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Improvement in ARDS patient's mortality rate</measure>
    <time_frame>within 10 days of ARDS diagnosis</time_frame>
    <description>Days to weaning from ventilator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit Length of Stay</measure>
    <time_frame>subject will be followed until discharged from the ICU, has deceased, or study duration has reached 10days from time of enrollment, whichever is first</time_frame>
    <description>improvement in clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Mechanical Ventilation</measure>
    <time_frame>subject will be followed until mechanical ventilation has been discontinued, the subject has deceased, or study duration has reached 10 days from time of enrollment, whichever is first</time_frame>
    <description>improvement in respiratory functions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Acute Respiratory Distress</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>conventional treatment (corticosteroids, mechanical ventilation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>test group (vitamin C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose vitamin c iv infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin c</intervention_name>
    <description>vitamin c IV 10 G</description>
    <arm_group_label>test group (vitamin C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All ARDS cases presenting to the Chest department ICU within 48 hours of diagnosis&#xD;
&#xD;
          2. who don't have an exclusion criteria will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy to Vitamin C&#xD;
&#xD;
          2. Inability to obtain consent;&#xD;
&#xD;
          3. Age &lt; 18 years;&#xD;
&#xD;
          4. More than 48 hours since meeting ARDS criteria;&#xD;
&#xD;
          5. Pregnancy or breast feeding,&#xD;
&#xD;
          6. Moribund patient not expected to survive 24 hours;&#xD;
&#xD;
          7. Patients not eligible to CPR&#xD;
&#xD;
          8. Active kidney stone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nada Farrag, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Misr International University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Embaba Chest Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>December 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Misr International University</investigator_affiliation>
    <investigator_full_name>Nada Hazem Farrag</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

